Follitropin delta combined with menotropin in patients at risk for poor ovarian response during in vitro fertilization cycles: a prospective controlled clinical study

• Published in: Reproductive biology and endocrinology 2024-01, Vol.22 (1), p.7-7, Article 7
• Main Authors: Duarte-Filho, Oscar Barbosa, Miyadahira, Eduardo Hideki, Matsumoto, Larissa, Yamakami, Lucas Yugo Shiguehara, Tomioka, Renato Bussadori, Podgaec, Sergio
• Format: Article
• Language: English
• Subjects: 17β-Estradiol; Agonists; Algorithms; Blastocysts; Care and treatment; Cetrorelix; Chorionic gonadotropin; Clinical trials; Controlled ovarian stimulation; Diagnosis; Eggs; Einstein, Albert (1879-1955); Embryo transfer; Embryology; Embryos; Endometriosis; Estrogen; Fertilization in vitro; Follicle-stimulating hormone; Follicles; Follitropin delta; Glycoproteins; Gonadotropin-releasing hormone; Gonadotropins; Health aspects; Hormones; Implantation; In vitro fertilization; Infertility; Infertility, Female; Intervention; Measurement; Menotropin; Menstruation; Miscarriage; Ovarian hyperstimulation syndrome; Ovaries; Ovulation; Patient outcomes; Patients; Pharmaceutical industry; Pharmaceuticals; Pituitary; Pituitary (anterior); Poor ovarian response; Pregnancy; Software; Variables
• ISSN: 1477-7827; 1477-7827
• DOI: 10.1186/s12958-023-01172-9

The maximum daily dose of follitropin delta for ovarian stimulation in the first in vitro fertilization cycle is 12 μg (180 IU), according to the algorithm developed by the manufacturer, and based on patient's ovarian reserve and weight. This study aimed to assess whether 150 IU of menotropin combined with follitropin delta improves the response to stimulation in women with serum antimullerian hormone levels less than 2.1 ng/mL. This study involved a prospective intervention group of 44 women who received 12 μg of follitropin delta combined with 150 IU of menotropin from the beginning of stimulation and a retrospective control group of 297 women who received 12 μg of follitropin delta alone during the phase 3 study of this drug. The inclusion and exclusion criteria and other treatment and follow-up protocols in the two groups were similar. The pituitary suppression was achieved by administering a gonadotropin-releasing hormone (GnRH) antagonist. Ovulation triggering with human chorionic gonadotropin or GnRH agonist and the option of transferring fresh embryos or using freeze-all strategy were made according to the risk of developing ovarian hyperstimulation syndrome. Women who received follitropin delta combined with menotropin had higher estradiol levels on trigger day (2150 pg/mL vs. 1373 pg/mL, p